TABLE 3.
Metabolic and endocrine parameters by treatment and salt sensitivity
Low salt | High salt placebo | High salt fenofibrate | |
---|---|---|---|
Triglycerides (mg/dl) | |||
Salt-resistant | 74.2 ± 34.1 | 76.6 ± 35.8 | 56.6 ± 28.3a,b |
Salt-sensitive | 83.9 ± 31.8 | 82.4 ± 25.6 | 59.4 ± 18.1a,b |
All | 78.6 ± 32.9 | 79.1 ± 31.4 | 57.8 ± 24.1a,b |
| |||
Fasting glucose (mg/dl) | |||
Salt-resistant | 92.4 ± 10.4 | 94.5 ± 12.6 | 93.3 ± 10.5 |
Salt-sensitive | 95.6 ± 11.4 | 92.6 ± 10.8 | 88.8 ± 6.9a |
All | 93.8 ± 10.8 | 93.5 ± 11.6 | 91.3 ± 9.3 |
| |||
Weight (kg) | |||
Salt-resistant | 82.6 ± 17.3 | 83.0 ± 17.0 | 83.0 ± 17.4 |
Salt-sensitive | 91.5 ± 27.1 | 92.5 ± 26.3 | 92.1 ± 26.5 |
All | 86.6 ± 22.3 | 87.3 ± 21.9a | 87.1 ± 22.0a |
| |||
Urinary sodium (mmol/day) | |||
Salt-resistant | 28.0 ± 24.5 | 187.1 ± 74.5a | 181.8 ± 74.2a |
Salt-sensitive | 21.4 ± 13.8 | 204.9 ± 73.5a | 216.0 ± 70.5a |
All | 25.0 ± 20.3 | 195.1 ± 73.4a | 197.2 ± 73.4a |
| |||
Urinary potassium (mmol/day) | |||
Salt-resistant | 79.6 ± 16.8 | 90.2 ± 30.9 | 101.3 ± 31.5a |
Salt-sensitive | 67.5 ± 19.9 | 96.2 ± 40.8a | 97.9 ± 40.3a |
All | 74.1 ± 18.9 | 92.9 ± 35.2a | 99.8 ± 35.1a |
| |||
Urine creatinine (g/day) | |||
Salt-resistant | 1.41 ± 0.45 | 1.33 ± 0.36 | 1.26 ± 0.44 |
Salt-sensitive | 1.66 ± 0.57 | 1.50 ± 0.71 | 1.40 ± 0.62 |
All | 1.53 ± 0.51 | 1.41 ± 0.55 | 1.32 ± 0.52a |
| |||
Aldosterone (pg/ml) | |||
Salt-resistant | 164.7 ± 75.8 | 76.8 ± 32.7a | 81.2 ± 40.5a |
Salt-sensitive | 141.6 ± 59.9 | 64.6 ± 20.6a | 63.8 ± 19.3a |
All | 154.2 ± 68.9 | 71.3 ± 28.1a | 73.6 ± 33.7a |
| |||
PRA (ng Ang l/ml per h) | |||
Salt-resistant | 3.7 ± 3.1 | 0.78 ± 0.60a | 0.67 ± 0.41a |
Salt-sensitive | 2.5 ± 1.7 | 0.71 ± 0.65a | 0.51 ± 0.46a,b |
All | 3.2 ± 2.6 | 0.75 ± 0.62a | 0.60 ± 0.44a |
| |||
Plasma norepinephrine (pg/ml) | |||
Salt-resistant | 244.1 ± 83.5 | 173.8 ± 79.3a | 192.5 ± 112.2a |
Salt-sensitive | 260.1 ± 94.5 | 176.6 ± 93.9a | 176.2 ± 80.0a |
All | 251.3 ± 87.5 | 175.1 ± 84.9a | 185.4 ± 98.3a |
| |||
Urine DHPG (μg/day) | |||
Salt-resistant | 134.7 ± 118.3 | 40.1 ± 23.9a | 64.5 ± 57.1a,b |
Salt-sensitive | 85.1 ± 45.8 | 47.9 ± 31.1a | 43.8 ± 32.9a |
All | 112.3 ± 94.9 | 43.6 ± 27.2a | 55.1 ± 48.1a |
| |||
Urine norepinephrine (μg/day) | |||
Salt-resistant | 133.1 ± 141.2 | 33.8 ± 34.0a | 58.4 ± 88.8a |
Salt-sensitive | 93.4 ± 117.9 | 33.2 ± 33.3a | 34.5 ± 46.8a |
All | 115.2 ± 130.6 | 33.5 ± 33.1a | 47.6 ± 72.8a |
| |||
Urine epinephrine (μg/day) | |||
Salt-resistant | 17.3 ± 35.4 | 4.1 ± 4.0 | 8.1 ± 8.4b |
Salt-sensitive | 8.3 ± 7.2 | 6.6 ± 11.3 | 3.8 ± 3.9a |
All | 13.2 ± 26.7 | 5.2 ± 8.1 | 6.2 ± 7.0 |
| |||
Urine dopamine (μg/day) | |||
Salt-resistant | 560.0 ± 717.1 | 167.3 ± 113.7a | 234.3 ± 171.9 |
Salt-sensitive | 346.0 ± 249.5 | 200.9 ± 118.8a | 166.0 ± 129.9a |
All | 463.3 ± 559.4 | 182.5 ± 115.4a | 203.5 ± 115.8a |
Data presented as N or mean ± SD. DHPG, dihydroxylphenylglycol; PRA, plasma renin activity.
P <0.05 versus low salt.
P <0.05 versus high salt placebo.